Management of Antiplatelet Therapy in Dengue Fever

Introduction to Antiplatelet Therapy Risks

Antiplatelet medications like aspirin and clopidogrel have a prolonged effect of 5-7 days after discontinuation, crucial in managing patients with dengue fever, as acknowledged by the American Heart Association 1
Aspirin irreversibly inhibits cyclooxygenase, preventing thromboxane A2 production, supported by evidence from 2
Clopidogrel irreversibly blocks the P2Y12 ADP receptor on platelets, as stated in 2

Patients on antiplatelet therapy for primary prevention should discontinue both aspirin and clopidogrel and resume therapy only after platelet count recovery and resolution of dengue, as per general medical guidelines 1
For patients on antiplatelet therapy for secondary prevention, temporary discontinuation of both medications during the acute phase of dengue is recommended, with careful consideration of the patient's cardiac risk factors 1
Daily complete blood count to monitor platelet trends, close observation for bleeding manifestations, and monitoring for signs of thrombotic complications are essential in managing patients with dengue fever on antiplatelet therapy 1

The World Health Organization implies that NSAIDs, including aspirin, are contraindicated in dengue, and alternative approaches such as acetaminophen should be used for analgesic and antipyretic purposes, although specific guidance from WHO is not cited here 1
The American College of Cardiology recommends using acetaminophen (paracetamol) as the safest option for pain relief without antiplatelet effects (Strength of evidence: High) 3
If an NSAID is needed, consider using with a proton pump inhibitor (PPI) to reduce GI bleeding risk, as recommended by the American College of Cardiology (Guideline society: American College of Cardiology) 3

The antiplatelet effect of aspirin and clopidogrel persists for 5-7 days after discontinuation, and therapy should be resumed as soon as platelet count recovers and bleeding risk subsides, based on the pharmacokinetics of these medications 1
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel together increases bleeding risk significantly, according to the American Heart Association 4
The European Society of Cardiology recommends that "long-term DAPT in patients with PAD is not recommended" (Strength of evidence: Moderate) 5
Post-acute coronary syndrome or stent placement, DAPT may be indicated for a limited time (typically 1-12 months depending on stent type), according to the American Heart Association 4

Ibuprofen can interfere with the antiplatelet effects of aspirin, potentially reducing its cardioprotective benefits, and is not recommended for patients on dual antiplatelet therapy (aspirin plus clopidogrel) due to increased bleeding risk, according to the American Heart Association and American College of Cardiology 6, 3
To minimize interactions, take ibuprofen at least 30 minutes after immediate-release aspirin or at least 8 hours before aspirin ingestion, as recommended by the American Heart Association and American College of Cardiology 7, 6, 8
Consider alternative NSAIDs that don't interfere with aspirin's effects, such as diclofenac, which is relatively COX-2 selective and does not interfere with aspirin's antiplatelet effects (Strength of evidence: Moderate) 9, 10

Patients with a history of peptic ulcer disease, advanced age, renal impairment, concomitant anticoagulant use, or history of GI bleeding have even higher bleeding risk with this combination, according to the American Heart Association 4
The American Heart Association recommends that "triple therapy should only be reserved for patients at the highest risk for thrombotic complications, and triple therapy should ideally not exceed 30 days" (Strength of evidence: High) 4
The combination of Plavix (clopidogrel), aspirin, and meloxicam is not recommended due to significantly increased bleeding risk without additional cardiovascular benefit, as per the American Heart Association 4